Broken String Biosciences

Broken String Biosciences is a private, platform technology company providing essential tools for the gene therapy development sector. Its core innovation, the INDUCE-seq® platform, directly detects DNA breaks caused by gene editors like CRISPR, offering a more accurate and scalable method for assessing on- and off-target effects compared to traditional indirect assays. The company is positioned to capitalize on growing regulatory demands for empirical, genome-wide safety data, aiming to become the standard for de-risking gene editing programs from discovery through IND-enabling studies. Recent leadership changes and a strategic rebrand underscore its focus on commercial expansion.

INDUCE-seq®: A PCR-free, in situ platform that directly labels and captures DNA double-strand breaks in cells for unbiased, genome-wide on- and off-target analysis of gene editing events. It integrates wet-lab assays with bioinformatics to provide actionable data for guide selection and safety assessment.

Broken String competes with legacy off-target detection methods (e.g., GUIDE-seq, CIRCLE-seq), specialized CROs offering sequencing-based services, and other platform companies developing novel genomics assays. Its primary differentiation is the direct, PCR-free measurement of DNA breaks in cells, which it positions as more accurate and scalable than indirect, outcome-based assays.